TG
NKTR icon

TCW Group’s Nektar Therapeutics NKTR Stock Holding History

TCW Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-4,124
Closed -$880K – 676
2016
Q2 		$880K Hold
4,124
– – 0.01% 510
2016
Q1 		$851K Sell
4,124
-475
-10% -$91.2K 0.01% 528
2015
Q4 		$1.16M Buy
4,599
+342
+8% +$70.3K 0.01% 465
2015
Q3 		$700K Sell
4,257
-1,301
-23% -$230K 0.01% 599
2015
Q2 		$1.04M Buy
+5,558
New +$956K 0.01% 519

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

TCW Group's NKTR Position: Q3 2016 in Review

TCW Group sold out of Nektar Therapeutics (NKTR) in Q3 2016, closing a stake of 4,124 shares — an estimated $880K sold.

TCW Group first reported a position in NKTR in Q2 2015 and held it in 5 quarters. The position peaked at $1.16M in Q4 2015. 194 funds tracked by Wall St. Rank hold NKTR as of Q3 2016.

  • TCW Group reported no remaining Nektar Therapeutics position as of Q3 2016 after selling out during the quarter.
  • TCW Group sold 4,124 Nektar Therapeutics shares in Q3 2016, an estimated $880K.
  • TCW Group first reported a position in Nektar Therapeutics in Q2 2015 and held it in 5 quarters.
  • TCW Group's Nektar Therapeutics position peaked at $1.16M in Q4 2015.
  • 194 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2016.

Based on TCW Group's 13F filing for Q3 2016, filed 14 Nov 2016.